Janetta Iwanicki, MD

Publications

• Rockhill KM, Black JC, Iwanicki J, Abraham A. Polysubstance Use Profiles Among the General Adult Population, United States, 2022. Am J Public Health. 2025 May;115(5):747-757. PubMed PMID: 40112266
• Rockhill KM, Bau GE, DeVeaugh-Geiss A, Chilcoat H, Dart R, Iwanicki J, Black JC. Buprenorphine, oxycodone, hydrocodone, and methadone mortality in the United States (2010?2017). J Am Coll Emerg Physicians Open. 2024 Oct;5(5):e13338. PubMed PMID: 39449817
• Severtson SG, Gurrola MC, Parrino MW, Ellis MS, Cicero TJ, Iwanicki JL, Dart RC. Abuse of tapentadol compared to other atypical opioids among individuals entering treatment for opioid use disorders. J Opioid Manag. 2023 Sep-Oct;19(5):445-453. PubMed PMID: 37968978
• Severtson SG, Haanschoten EE, Iwanicki J, Dart RC. Differences in severity of poison centers exposures involving XTAMPZA(®) ER versus other opioid analgesics. Pain Manag. 2023 Sep;13(9):519-527. PubMed PMID: 37850331
• Black JC, Burkett HL, Rockhill KM, Olson R, Dart RC, Iwanicki J. Initiation Patterns and Transitions Among Adults Using Stimulant Drugs: Latent Transition Analysis. J Med Internet Res. 2023 Oct 5;25:e46747. PubMed PMID: 37796607
• Rockhill KM, Olson R, Dart RC, Iwanicki JL, Black JC. Differing Behaviors Around Adult Nonmedical Use of Prescription Stimulants and Opioids: Latent Class Analysis. J Med Internet Res. 2023 Sep 20;25:e46742. PubMed PMID: 37728974
• Jewell J, Black J, Ellis M, Olsen H, Iwanicki J, Dart R. Correction to: A Cross-Sectional Study of Tampering in Xtampza ER, an Abuse-Deterrent Formulation of an Extended-Release Opioid, in a Treatment Center Population. Clin Drug Investig. 2023 May;43(5):379. PubMed PMID: 37040042
• Jewell J, Black J, Ellis M, Olsen H, Iwanicki J, Dart R. A Cross-Sectional Study of Tampering in Xtampza ER, an Abuse-Deterrent Formulation of an Extended-Release Opioid, in a Treatment Center Population. Clin Drug Investig. 2023 Mar;43(3):197-203. PubMed PMID: 36859697
• Mutter R, Black J, Iwanicki J. Changes in the Street Prices of Prescription Opioids During the COVID-19 Pandemic. Psychiatr Serv. 2023 Jan 1;74(1):63-65. PubMed PMID: 35770425
• Black JC, Rockhill KM, Dart RC, Iwanicki J. Clustering patterns in polysubstance mortality in the United States in 2017: a multiple correspondence analysis of death certificate data. Ann Epidemiol. 2023 Jan;77:119-126. PubMed PMID: 35378292
• Mutter R, Black J, Iwanicki J. Changes in the Street Prices of Prescription Opioids During the COVID-19 Pandemic. Psychiatr Serv. 2023 Jan 1;74(1):63-65. PubMed PMID: 35770425
• Black JC, Rockhill KM, Dart RC, Iwanicki J. Clustering patterns in polysubstance mortality in the United States in 2017: a multiple correspondence analysis of death certificate data. Ann Epidemiol. 2023 Jan;77:119-126. PubMed PMID: 35378292
• Hockenhull J, Wood DM, Fonseca F, Guareschi M, Scherbaum N, Iwanicki JL, Dart RC, Dargan PI. The association between the availability of over the counter codeine and the prevalence of non-medical use. Eur J Clin Pharmacol. 2022 Jun;78(6):1011-1018. PubMed PMID: 35244726
• Palamar JJ, Cottler LB, Goldberger BA, Severtson SG, Grundy DJ, Iwanicki JL, Ciccarone D. Trends in characteristics of fentanyl-related poisonings in the United States, 2015-2021. Am J Drug Alcohol Abuse. 2022 Jul 4;48(4):471-480. PubMed PMID: 35704785
• Fischer LJ, Severtson SG, Gurrola MC, Iwanicki JL, Green JL, Dart RC. Changes in Hydrocodone Misuse Exposures Reported to U.S. Poison Centers Following Rescheduling in 2014. Subst Use Misuse. 2022;57(7):1097-1103. PubMed PMID: 35450512
• Black JC, Amioka E, Iwanicki JL, Dart RC, Monte AA. Evaluation of Cannabis Use Among US Adults During the COVID-19 Pandemic Within Different Legal Frameworks. JAMA Netw Open. 2022 Nov 1;5(11):e2240526. PubMed PMID: 36342719